DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.
SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM ...
Lilly, a sweet and social 1-year-old old terrier with a lot of positive qualities, is available for adoption at The Cat House ...
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.
Lilly continues full-court press against breast cancer with women's March Madness event sponsorships
As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women ...
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback